

# Amaya Viros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/84899/publications.pdf>

Version: 2024-02-01

46  
papers

5,100  
citations

257450

24  
h-index

206112

48  
g-index

55  
all docs

55  
docs citations

55  
times ranked

8758  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	27.0	978
2	Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin $\beta$ 1/FAK Signaling. <i>Cancer Cell</i> , 2015, 27, 574-588.	16.8	485
3	ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma. <i>Cancer Cell</i> , 2011, 20, 229-245.	16.8	342
4	Improving Melanoma Classification by Integrating Genetic and Morphologic Features. <i>PLoS Medicine</i> , 2008, 5, e120.	8.4	322
5	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	9.4	300
6	$\beta$ -Catenin induces immortalization of melanocytes by suppressing <i>p16<sup>INK4a</sup></i> expression and cooperates with N-Ras in melanoma development. <i>Genes and Development</i> , 2007, 21, 2923-2935.	5.9	283
7	Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. <i>Nature</i> , 2014, 511, 478-482.	27.8	208
8	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	9.4	208
9	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A. <i>Cancer Cell</i> , 2011, 19, 45-57.	16.8	190
10	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. <i>Cancer Cell</i> , 2015, 27, 85-96.	16.8	188
11	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. <i>European Journal of Endocrinology</i> , 2011, 165, 315-322.	3.7	184
12	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies. <i>Science Translational Medicine</i> , 2010, 2, 35ra41.	12.4	142
13	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. <i>Nature Communications</i> , 2014, 5, 4255.	12.8	140
14	Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A. <i>Cancer Discovery</i> , 2012, 2, 344-355.	9.4	133
15	Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. <i>Molecular Oncology</i> , 2016, 10, 73-84.	4.6	129
16	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. <i>Science Signaling</i> , 2014, 7, ra30.	3.6	113
17	Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 210-215.	3.3	101
18	Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma. <i>Nature Medicine</i> , 2019, 25, 221-224.	30.7	75

#	ARTICLE	IF	CITATIONS
19	Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. <i>Nature Communications</i> , 2017, 8, 14909.	12.8	69
20	Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108.	1.8	63
21	Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic <i>NRAS</i> in Melanocytes. <i>Cancer Discovery</i> , 2013, 3, 458-469.	9.4	61
22	A caveolin-dependent and PI3K/AKT-independent role of PTEN in $\beta$ -catenin transcriptional activity. <i>Nature Communications</i> , 2015, 6, 8093.	12.8	58
23	Ultraviolet light and melanoma. <i>Journal of Pathology</i> , 2018, 244, 578-585.	4.5	47
24	Clinical, molecular and biochemical characterization of nine Spanish families with Conradi-Häxlermann-Happle syndrome: new insights into X-linked dominant chondrodysplasia punctata with a comprehensive review of the literature. <i>British Journal of Dermatology</i> , 2012, 166, 830-838.	1.5	40
25	Ultraviolet light-induced collagen degradation inhibits melanoma invasion. <i>Nature Communications</i> , 2021, 12, 2742.	12.8	25
26	Mind the IQGAP. <i>Cancer Cell</i> , 2013, 23, 715-717.	16.8	23
27	Nodular Melanoma: A Histopathologic Entity?. <i>Acta Dermato-Venereologica</i> , 2018, 98, 460-462.	1.3	22
28	Eruptive Juvenile Xanthogranuloma Associated with Relapsing Acute Lymphoblastic Leukemia. <i>Pediatric Dermatology</i> , 2008, 25, 487-488.	0.9	18
29	VIGNETTES. <i>Archives of Dermatology</i> , 2005, 141, 1053-4.	1.4	15
30	Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor-Induced Cutaneous Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 274-276.	0.7	14
31	The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. <i>Annals of Oncology</i> , 2021, 32, 269-278.	1.2	14
32	New insights into naevoid melanomas: a clinicopathological reassessment. <i>Histopathology</i> , 2017, 71, 943-950.	2.9	13
33	Molecular subtype, biological sex and age shape melanoma tumour evolution. <i>British Journal of Dermatology</i> , 2021, 184, 328-337.	1.5	13
34	Histologic Features Associated With an Invasive Component in Lentigo Maligna Lesions. <i>JAMA Dermatology</i> , 2019, 155, 782.	4.1	12
35	Molecular characterization of fast-growing melanomas. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 312-321.	1.2	11
36	Female Immunity Protects from Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3215-3223.	7.0	10

#	ARTICLE	IF	CITATIONS
37	<sup>G12D</sup><scp>NRAS</scp> and kinaseâ€dead <scp>BRAF</scp> cooperate to drive naevogenesis and melanomagenesis. Pigment Cell and Melanoma Research, 2014, 27, 1162-1166.	3.3	8
38	Cutaneous melanoma primary site is linked to nevus density. Oncotarget, 2017, 8, 98876-98886.	1.8	6
39	V600EBraf::Tyr-CreERT2::K14-Kitl Mice Do Not Develop Superficial Spreading-Like Melanoma: Keratinocyte Kit Ligand Is Insufficient to â€Translocateâ€V600EBraf-Driven Melanoma to the Epidermis. Journal of Investigative Dermatology, 2012, 132, 488-491.	0.7	5
40	So You Can Teach Old Fibroblasts New Tricks. Cancer Discovery, 2016, 6, 581-583.	9.4	5
41	Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development. Cancers, 2021, 13, 5219.	3.7	5
42	Keratosis lichenoides chronica masquerading as discoid lupus erythematosus. Clinical and Experimental Dermatology, 2013, 38, 327-329.	1.3	3
43	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. ESMO Open, 2020, 5, e000707.	4.5	3
44	Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma. Journal of Investigative Dermatology, 2021, , .	0.7	2
45	Hooked on <scp>UVR</scp>. Pigment Cell and Melanoma Research, 2014, 27, 1009-1010.	3.3	1
46	New biomarkers improve stratification of patients with melanoma. British Journal of Dermatology, 2020, 182, 5-6.	1.5	1